(Nasdaq: MGX) (the "Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback